# The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT

> **NCT05596968** · — · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 37 (estimated)

## Conditions studied

- Acute Myeloid Leukemia With FLT3/ITD Mutation
- Allogeneic Hematopoietic Stem Cell Transplantation

## Interventions

- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT05596968
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2022-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05596968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05596968, "The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05596968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*